•  NIH SMALL MOLECULE REPOSITORY

Hamburg, Germany - 19 September 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health (NIH), Department of Health and Human Services, for the operation of a Small Molecule Repository. The contract (funded in its entirety by NIH) covers a period of up to ten years and has a total estimated value of up to EUR 60 million (approx. USD 75 million).

The NIH Small Molecule Repository (SMR) contract will continue to provide services initiated previously under contract N01MH41001 to acquire, store, maintain, and distribute the current library collection, supporting certain NIH-supported screening Centers conducting high-throughput screening (HTS) for probe and drug discovery. As part of continuing efforts to expand and support translational science, this contract resource will now be made available to select outside collaborators (in addition to the NIH screening efforts/programs). Library development efforts will continue to shape, improve, and expand the collection.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: 'We are delighted the NIH has elected to award Evotec this long term contract which further validates our entry into compound management through our acquisition of Compound Focus Inc. in June 2011. This long term contract will be managed through our San Francisco subsidiary however we are also currently developing options to expand our compound management capabilities into the East Coast of USA and also into Europe.'

ABOUT THE NIH SMALL MOLECULE REPOSITORY

The NIH Small Molecule Repository, initiated in 2004, was developed as part of the Molecular Libraries Program, an NIH Common Fund Initiative. The goals of the SMR are to identify, acquire, maintain, and distribute a collection of chemically diverse compounds with known and unknown biological activities for use in high-throughput screening (HTS). These compounds are intended to serve as starting material for the development of chemical probes to explore basic biology, as well as leads for therapeutics development.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.